Therefore, assessing the expression levels of CHI3L1 can facilitate the identification of GPL patients at elevated risk for progression to GC, while also serving as a valuable reference for clinicians in the development of treatment strategies. The gene discussed is IL31RA; the disease is gastric cancer.